MedTrace Logo

Adalimumab in Rheumatoid Arthritis. An Investigation of Wholebody MRI, Conventional MRI, CT and Circulating Biomarkers

NCT01029613 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2015-08-19

No results posted yet for this study

Summary

Adalimumab in rheumatoid arthritis. An investigation of changes in disease activity and course of joint destruction by use of 3 Tesla Whole-Body MRI, dedicated 3 Tesla MRI and CT of the hand, and soluble biomarkers. Furthermore to compare ultrasound examination with wholebody MRI etc.

Conditions

Interventions

DRUG

Adalimumab

sc. inj. Humira 40 mg every other week from week 0 to 52

Sponsors & Collaborators

  • Glostrup University Hospital, Copenhagen

    lead OTHER

Principal Investigators

  • Mikkel Østergaard, Professor · Dep. of Rheumatology, Glostrup Hospital

  • Susanne J Pedersen, MD · Dep. of Rheumatology, Glostrup Hospital

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2013-07-31
Completion
2013-07-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01029613 on ClinicalTrials.gov